The Center for HIV / AIDS Vaccine Immunology & Immunogen Discovery (CHAVI-ID) is an advanced vaccine for accelerating the development of HIV thanks to advanced technologies and advanced knowledge in immunological and clinical research, bioinformatics genomics and proteomics.
HIV is not only a major public health problem, but it can also be prevented by vaccination, but also because it infects people with a virus that targets their immune system - which makes them more prone to other infections. The virus kills immune helper T cells called CD4 + cells, which are the coordinates of the human immune system. This is where the name "acquire immunodeficiency syndrome comes from": when HIV kills enough CD4 + cells, the immune system of the infected person can fight off infections that could be easily controlled. When the number of CD4 + cells drops below a certain point, a person is considered to have progressed from HIV infection to AIDS.
The HIV vaccines discussed above are intended to be preventive vaccines. In other words, they are designed to prevent the body from infecting HIV. A therapeutic vaccine is a different type of vaccine design, which would have been used after the infection had already occurred. Most investigators believe that a therapeutic HIV vaccine is not a cure - it is a potential cause of the virus and will not stop antiretroviral therapy. However, such a vaccine could stimulate the body's immune response to the virus.